also prove to be useful as an adjuvant for a future vaccine for the SARS-CoV-2 virus, if this enhancing effect can be demonstrated to apply to the appropriate antigen(s). Cancer Found on a number of cancer cell types. Possible cancer therapy target. See milatuzumab. Axial spondyloarthritis Autoantibodies against CD74 have been identified as promising biomarkers in the early diagnosis of the autoimmune disease called axial spondyloarthritis (non-radiographic axial spondyloarthritis and radiographic axial spondyloarthritis / Ankylosing spondylitis). Interactions CD74 receptor interacts with the cytokine Macrophage migration inhibitory factor (MIF) to mediate some of its functions. Recovery functions CD74 receptor is expressed on the surface of different cell types. Interaction between MIF cytokine and its cell membrane receptor CD74 activates pro-survival and proliferative pathways that protect against injury and promote healing in different parts of the body. History The invariant chain was first described by Patricia P. Jones, Donal B. Murphy, Derek Hewgill, and Hugh McDevitt at Stanford. The nomenclature "Ii" comes from an Ix-based naming system (I for Immune) that predates the naming of the Major Histocompatibility Complex. See also Cluster of differentiation Milatuzumab the first Mab to target CD74 References Further reading External links Overview at Davidson College (student generated) School of Crystallography The Invariant Chain Clusters of differentiation Immune system